Displaying One Session

Room C Mini Oral session
Date
12.12.2019
Time
10:45 - 11:45
Location
Room C
Chairs
  • J. Haanen (Amsterdam, Netherlands)
  • I. Melero (Pamplona, Spain)
Mini Oral session 1 Mini Oral session

DOI session

Lecture Time
10:45 - 10:45
Session Name
Location
Room C, Geneva Palexpo, Geneva, Switzerland
Date
12.12.2019
Time
10:45 - 11:45
Mini Oral session 1 Mini Oral session

LBA2 - First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: safety, pharmacokinetics (PK) and immunogenicity in CASPIAN

Presentation Number
LBA2
Lecture Time
10:45 - 10:50
Speakers
  • M. Özgüroğlu (Istanbul, Turkey)
Session Name
Location
Room C, Geneva Palexpo, Geneva, Switzerland
Date
12.12.2019
Time
10:45 - 11:45
Authors
  • M. Özgüroğlu (Istanbul, Turkey)
  • J. Goldman (Los Angeles, United States of America)
  • N. Reinmuth (Gauting, Germany)
  • Y. Chen (Grand Rapids, MI, United States of America)
  • M. Dvorkin (Omsk, Russian Federation)
  • D. Trukhin (Odessa, Ukraine)
  • G. Statsenko (Omsk, Russian Federation)
  • K. Hotta (Okayama, Japan)
  • J. Ji (Changwon, Korea, Republic of)
  • M. Hochmair (Vienna, Austria)
  • O. Voitko (Kiev, Ukraine)
  • L. Havel (Prague, Czech Republic)
  • A. Poltoratskiy (St Petersburg, Russian Federation)
  • G. Losonczy (Budapest, Hungary)
  • F. Verderame (Palermo, Italy)
  • M. Thomas (Gaithersburg, MD, United States of America)
  • Y. Zheng (Mountain View, CA, United States of America)
  • A. Lloyd (Alderley Park, United Kingdom)
  • H. Jiang (Gaithersburg, MD, United States of America)
  • L. Paz-Ares (Madrid, Spain)

Abstract

Background

CASPIAN is a Phase 3, open-label study of 1L platinum-etoposide (EP) ± durvalumab (D) ± tremelimumab (T) for pts with ES-SCLC. D+EP significantly improved OS vs EP alone (HR 0.73 [95% CI 0.59–0.91]; p=0.0047) at a planned interim analysis. Rates of all-cause AEs and AEs leading to discontinuation were similar between arms. Immune-mediated AEs (imAEs) were higher with D+EP vs EP, while numerically fewer pts in the D+EP arm had serious AEs (SAEs; 30.9 vs 36.1%). Here we present further safety, PK and immunogenicity results.

Methods

Treatment-naïve pts with ES-SCLC were randomised 1:1:1 to D 1500 mg + EP q3w, D 1500 mg + T 75 mg + EP q3w, or EP q3w. Investigator’s choice of carboplatin or cisplatin was allowed. In the IO arms, pts received 4 cycles of EP, followed by D 1500 mg q4w until progression; up to 6 cycles of EP and optional PCI were permitted in the control arm. Safety, PK and immunogenicity were secondary endpoints.

Results

265 pts received D+EP and 266 received EP. Serum concentrations were within the expected range for D and were similar across both arms for EP. Of 201 anti-drug antibody (ADA)-evaluable pts in the D+EP arm, 11 (5.5%) were +ve for ADA to D at baseline only; no pts were +ve for treatment-emergent ADA or neutralising antibodies. The most common AEs, grade 3/4 AEs and SAEs in both arms were haematological toxicities. These were well managed using standard therapies per local practice; colony stimulating factor use was 50.4% in the D+EP arm and 56.9% in the EP arm, and 12.7% and 20.8% received blood transfusions. When events that coincided with cycles 5 and 6 of EP in the control arm were removed, the overall SAE rate was similar between arms (30.9% for D+EP vs 30.1% for EP). Most imAEs were low grade, endocrine-related and managed with corticosteroid or endocrine therapy; median time to onset was generally >60 days (Table).

D+EP (n=265)

EP (n=266)

imAE (group term)*

Any grade, n (%)

Grade ≥3, n (%)

Median time to onset, days (range)

Any grade, n (%)

Grade ≥3, n (%)

Median time to onset,

days (range)

Any imAE

52 (20)

13 (5)

7 (3)

2 (1)

Hypothyroid

24 (9)

0

141
(42–283)

2 (1)

0

63
(62–64)

Hyperthyroid

14 (5)

0

85.5
(22–372)

0

0

Pneumonitis

7 (3)

2 (1)

191
(80–365)

2 (1)

2 (1)

177
(141–213)

Hepatic

7 (3)

6 (2)

93
(31–256)

0

0

Dermatitis/rash

4 (2)

0

33.5

(16–91)

2 (1)

0

31

(27–35)

Diarrhoea/colitis

4 (2)

1 (0.4)

28

(9–114)

1 (0.4)

0

64
(64–64)

Thyroiditis

4 (2)

0

144
(43–260)

0

0

Type 1 diabetes

4 (2)

4 (2)

104

(38–316)

0

0

*imAEs with incidence ≥2% in either arm are shown. Time from first dose to onset of any grade imAEs.

Conclusion

In CASPIAN, the incidence of ADA to D was low and the safety profile of D+EP was consistent with previous reports of both D and EP.

Clinical trial identification

NCT03043872 (release date: February 6, 2017)

Editorial acknowledgement

Medical writing support, which was in accordance with Good Publication Practice (GPP3) guidelines, was provided by Craig Turner, MSc, of Cirrus Communications (Macclesfield, UK), an Ashfield company, and was funded by AstraZeneca

Collapse
Mini Oral session 1 Mini Oral session

LBA5 - KRAS mutational status and efficacy in KEYNOTE-189: pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC

Presentation Number
LBA5
Lecture Time
10:50 - 10:55
Speakers
  • D. Rodriguez-Abreu (Gran Canaria, Spain)
Session Name
Location
Room C, Geneva Palexpo, Geneva, Switzerland
Date
12.12.2019
Time
10:45 - 11:45
Authors
  • S. Gadgeel (Ann Arbor, United States of America)
  • D. Rodriguez-Abreu (Gran Canaria, Spain)
  • E. Felip (Barcelona, Spain)
  • E. Esteban (Oviedo, Spain)
  • G. Speranza (Greenfield Park, QC, Canada)
  • M. Reck (Grosshansdorf, Germany)
  • R. Hui (Westmead, NSW, Australia)
  • M. Boyer (Camperdown, ACT, Australia)
  • E. Garon (Santa Monica, CA, United States of America)
  • H. Horinouchi (Chuo-ku, Japan)
  • R. Cristescu (Kenilworth, United States of America)
  • D. Aurora-Garg (Kenilworth, New Jersey, United States of America)
  • J. Lunceford (Kenilworth, NJ, United States of America)
  • J. Kobie (Kenilworth, United States of America)
  • M. Ayers (West Point, United States of America)
  • B. Piperdi (Whitehouse Station, United States of America)
  • M. Pietanza (Whitehouse Station, NJ, United States of America)
  • M. Garassino (Milan, Italy)

Abstract

Background

KRAS mutations are observed in ~25% of lung adenocarcinomas, with some studies suggesting it is a prognostic factor in NSCLC. We assessed the prevalence of KRAS mutations and their association with efficacy in an exploratory analysis of the KEYNOTE-189 study of pembrolizumab plus pemetrexed and platinum chemotherapy vs placebo plus chemotherapy as first-line therapy for metastatic nonsquamous NSCLC (NCT02578680).

Methods

Whole-exome sequencing (WES) was used to assess KRAS status and tumor mutational burden (TMB) in participants (pts) who had available tumor and matched-normal tissue. Descriptive analyses of the association of KRAS and KRAS G12C status with efficacy were included as part of this exploratory analysis, as was correlation between KRAS mutational status and shifts in TMB and PD-L1 expression distributions.

Results

289 (47%) of 616 pts had evaluable WES data from both tumor and normal DNA. 89 (31%) of 289 pts had KRAS mutation, including 37 (13%) G12C carriers. Pts with vs without KRAS mutations tended to have higher PD-L1 TPS (median [IQR] 30% [1-71] vs 5% [0-60]) and higher TMB (median [IQR] 204 [137-276] vs 141 [85-252] mut/exome). Outcomes of pembrolizumab plus chemotherapy and of placebo plus chemotherapy in pts with and without KRAS mutation and in KRAS G12C carriers are summarized in the Table. 95% CIs were wide given the modest frequency of KRAS mutation, particularly KRAS G12C, and the 2:1 randomization that resulted in small populations for placebo plus chemotherapy.

Conclusion

Based on this descriptive exploratory analysis, pembrolizumab plus pemetrexed and a platinum should be a standard first-line treatment for pts with metastatic nonsquamous NSCLC regardless of KRAS mutation status.

With Any KRAS Mutation With KRAS G12C Mutation Without Any KRAS Mutation

Pembro + Chemo

(N = 59)

Placebo + Chemo

(N = 30)
Pembro + Chemo
(N = 26)

Placebo + Chemo

(N = 11)

Pembro + Chemo

(N = 145)
Placebo + Chemo
(N = 55)
ORR, %
(95% CI)
40.7
(28.1-54.3)
26.7
(12.3-45.9)
50.0
(29.9-70.1)
18.2
(2.3-51.8)
47.6
(39.2-56.0)
10.9
(4.1-22.3)
PFS, median, mo (95% CI) 9 (7-14) 5 (5-9) 11 (6-18) 5 (5-NR) 9 (7-14) 5 (4-5)

PFS, HR (95% CI)

0.47 (0.29-0.77) 0.48 (0.22-1.06) 0.40 (0.29-0.57)
OS, median, mo (95% CI) 21 (16-NR) 14 (8-NR) 18 (11-NR) 25 (8-NR) 23 (19-NR) 9 (7-17)
OS, HR (95% CI) 0.79 (0.45-1.38) 1.14 (0.45-2.92) 0.55 (0.37-0.81)

Clinical trial identification

KEYNOTE-189, NCT02578680

Editorial acknowledgement

Joanne Tomassini and Melanie Leiby, both of Merck & Co., Inc., Kenilworth, NJ, USA, for writing support.

Collapse
Mini Oral session 1 Mini Oral session

35O - Phase I clinical trial of PD-1 knockout anti-MUC1 CAR-T cells in the treatment of patients with non-small cell lung cancer

Presentation Number
35O
Lecture Time
10:55 - 11:00
Speakers
  • Y. Lin (Sydney, Australia)
Session Name
Location
Room C, Geneva Palexpo, Geneva, Switzerland
Date
12.12.2019
Time
10:45 - 11:45
Authors
  • Y. Lin (Sydney, Australia)
  • S. Chen (Guangzhou, China)
  • S. Zhong (Guangzhou, China)
  • H. An (Guangzhou, China)
  • H. Yin (Guangzhou, China)
  • E. McGowan (Sydney, ACT, Australia)

Abstract

Background

Little has been done on assessing the safety and efficacy of programmed death-1 (PD-1) knockout (KO) engineered CART cells in cancer patients. Here we designed a clinical trial to evaluate the safety of PD-1 KO engineered anti-MUC1 CART cells for the treatment of patients with advanced non-small cell lung cancer (NSCLC). The primary endpoint was to evaluate the safety of the new treatment.

Methods

Patients (age ≥ 18) were recruited according to the criteria in NCT03525782. MUC1-specific CARs were constructed using the SM3 scFv. Following lenti-MUC1 CAR retroviral transduction, efficiency of transgenic expression was assessed by flow cytometry. PD-1 gene KO in the CAR positive T cells was achieved using the CRISPR-Cas9 system and validated by sequencing and flow cytometry. MUC1-CAR+/PD-1- T cells at a starting dose of 2.5x106/KG were infused over 60 mins. Following treatment, patients’ general condition, levels of lymphocytes, IL-6, hs-CRP, PCT, CYFRA21, NSE(E), and SCC were monitored. Circulating CART cells were checked regularly. Changes in tumor size were examined by MRI scans.

Results

Up to the study cutoff date, 19/9/2019, 20 patients diagnosed with NSCLC (IIIb to IV), were recruited. All participants received at least one cycle of anti-MUC1 CART cell treatment. Among the 20 treated patients, 8 received 1 cycle, 9 received 2 cycles, 2 received 3 cycles, and 1 received 4 cycles. Common adverse events (AEs) were acute fever (3 pts, 38.2-39.8 C), chills (2 pts), headache (1 pt), skin rash (1 pt), diarrhea (1 pt), and nausea & vomiting (1 pt). No grade 3-5 AEs and CRS was observed. Of the 20 assessed patients, 11 presented with stable disease while 9 had progressive disease. All patients had significant symptom improvements after infusion. Circulating CART cells gradually declined after infusion and the number dropped down to approximately 20% in 4 months after one cycle treatment, indicating the necessity of further cycles.

Conclusion

Our data suggests that the treatment with PD-1 disrupted anti- MUC1-CAR cells is safe and well tolerated by all NSCLC patients. Importantly no CRS was indicated in all cases. The efficacy of this unique combined therapy was still inconclusive and will be explored in our next phase study.

Clinical trial identification

NCT03525782.

Editorial acknowledgement

N/A

Legal entity responsible for the study

Guangzhou Anjie Biomedical Technology Co. Ltd.

Funding

Guangzhou Anjie Biomedical Technology Co. Ltd.

Disclosure

All authors have declared no conflicts of interest.

Collapse
Mini Oral session 1 Mini Oral session

46O - Impact of early introduction of steroid on immune-checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer treated

Presentation Number
46O
Lecture Time
11:00 - 11:05
Speakers
  • L. Mezquita (Villejuif, France)
Session Name
Location
Room C, Geneva Palexpo, Geneva, Switzerland
Date
12.12.2019
Time
10:45 - 11:45
Authors
  • A. De Giglio (Perugia, Italy)
  • L. Mezquita (Villejuif, France)
  • E. Auclin (Paris, France)
  • F. Blanc-Durand (Villejuif, France)
  • L. El-Amarti (Villejuif, France)
  • C. Caramella (Villejuif, France)
  • G. Martinez Bernal (Villejuif, France)
  • L. Hendriks (Maastricht, Netherlands)
  • R. Ferrara (Milan, Italy)
  • C. Naltet (Villejuif, France)
  • P. Lavaud (Villejuif, CEDEX 14, France)
  • A. Gazzah (Villejuif, France)
  • J. Adam (Villejuif, France)
  • D. Planchard (Villejuif, France)
  • N. Chaput (Villejuif, CEDEX, France)
  • B. Besse (Villejuif, CEDEX, France)

Abstract

Background

The use of steroids at baseline before ICI initiation has been associated with poor outcomes, particularly when their indication is related to cancer symptoms. It is poorly known if the initiation of steroids during the course of ICI impacts the outcomes.

Methods

Retrospective analysis of advanced NSCLC patients treated with ICI at Institute Gustave Roussy. Eligible: steroids-naïve at baseline, initiating steroids therapy (≥10 mg of prednisone-equivalent) within the first 8 weeks of ICI. We correlated steroid use with outcomes, including progression-free survival (PFS) and overall survival (OS).

Results

In an overall population of 424 patients treated with ICI, 250 were steroids-naïve at baseline. The median age was 63 years (range 30–92), most of them were male (65.5%), current or former smoker (90.6%), with non-squamous histology (76.1%) and ECOG PS 0/1 (76.8%). A total of 49 patients received early steroids: 39 patients for cancer-related indications [dyspnea (50%), brain metastasis (15.8%), pain (7.9%), superior vena cava syndrome (7.9%), fatigue (5.3%) and others (13.1%)]. For the 10 others indications were: immune-related adverse events (54.6%), COPD exacerbation (27.1%) and others (18.2%). Median (m) PFS and OS were 1.9 months (mo.) [95% CI, (1.77-2.40)] and 10 mo. [95% CI, (8.11-12.91)], respectively. Early introduction of steroids under ICI was associated with a shorter median (m) PFS (1.3 mo., P < 0.0001), and mOS (2.3 mo., P < 0.0001). Patients receiving steroids for cancer-related symptoms had significantly poorer outcomes with mPFS of 1.1 mo. [95% CI, 0.85-1.51] and mOS of 1.9 mo. [95% CI, (1.54-2.4)]. No differences were observed between the group of patients that started steroids for other indications [mPFS 2.7 mo. (1.21-NR); mOS 13.4 mo., (4.30-NR)] and the group without steroids [mPFS 2.6 mo. (2.20-3.94); mOS 13.8 mo. (11.4-18)]. Early steroids introduction for cancer-related symptoms was an independent prognostic factor for both poor PFS [HR 3.04; 95% CI, (1.38-6.66); P = 0.006] and OS [HR 1.21; 95%CI, (0.53-2.8); P < 0.0001].

Conclusion

Introduction of steroids within the first 8 weeks of ICI has no detrimental impact on prognosis if the indication is not related to cancer symptoms.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

L. Mezquita: Advisory / Consultancy: Roche Diagnostics; Speaker Bureau / Expert testimony: Bristol-Myers; Speaker Bureau / Expert testimony: Squibb; Speaker Bureau / Expert testimony: Tecnofarma; Speaker Bureau / Expert testimony: Roche; Speaker Bureau / Expert testimony: AstraZeneca; Travel / Accommodation / Expenses: Bristol-Myers; Travel / Accommodation / Expenses: Squibb; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Chugai; Research grant / Funding (institution), Mentorship Program: AstraZeneca. E. Auclin: Travel / Accommodation / Expenses: Mundipharma. C. Caramella: Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: MSD; Advisory / Consultancy: Roche; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Amgen. L. Hendriks: Research grant / Funding (institution): Roche; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Bristol-Myers Squibb; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Bristol-Myers Squibb; Non-remunerated activity/ies, Mentorship Program: AstraZeneca; Non-remunerated activity/ies, Webinars: Quadia. R. Ferrara: Advisory / Consultancy: MSD; Travel / Accommodation / Expenses: Pfizer. P. Lavaud: Travel / Accommodation / Expenses: Astellas-Pharma; Travel / Accommodation / Expenses: AstraZeneca; Travel / Accommodation / Expenses: Ipsen; Travel / Accommodation / Expenses: Janssen Oncology; Travel / Accommodation / Expenses: Mundi Pharma. A. Gazzah: Research grant / Funding (institution), Travel / Accommodation / Expenses: Boehringer Ingelheim; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Research grant / Funding (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Research grant / Funding (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Research grant / Funding (institution): Aduro Biotech; Research grant / Funding (institution): Agios Pharmaceuticals; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Argen-X Bvba; Research grant / Funding (institution): Arno Therapeutics; Research grant / Funding (institution): Astex Pharmaceuticals; Research grant / Funding (self), Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Aveo; Research grant / Funding (institution): Bayer Healthcare Ag; Research grant / Funding (institution): Bbb Technologies Bv; Research grant / Funding (institution): Beigene; Research grant / Funding (institution): Bioalliance Pharma; Research grant / Funding (institution): Biontech Ag; Research grant / Funding (institution): Blueprint Medicines; Research grant / Funding (institution): Bristol Myers Squibb; Research grant / Funding (institution): Celgene Corporation; Research grant / Funding (institution): Chugai Pharmaceutical Co.; Research grant / Funding (institution): Clovis Oncology, Daiichi Sankyo, Debiopharm S.A., Eisai, Exelixis, Forma, Gamamabs, Genentech, Inc., Gilead Sciences, Inc, Glaxosmithkline, Glenmark Pharmaceuticals, H3 Biomedicine, Inc, Hoffmann La Roche Ag, Incyte Corporation, Innate Pharma, Iris Servie; Research grant / Funding (self): Janssen Cilag; Non-remunerated activity/ies, Drug Supplied: AstraZeneca, Bayer, Bristol-Myers Squibb, Boringher Ingelheim, Johnson & Johnson, Lilly, Medimmune, Merck, NH TherAGuiX, Pfizer, Roche. J. Adam: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Bayer; Honoraria (self): MSD; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Takeda; Honoraria (self): Chugai. D. Planchard: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy: Celgene; Advisory / Consultancy, Research grant / Funding (institution): Daiichi Sankyo; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Merck; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: prIME Oncology; Advisory / Consultancy: Peer CME; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Research grant / Funding (institution): Medimmun; Research grant / Funding (institution): Sanofi-Aventis; Research grant / Funding (institution): Taiho Pharma; Research grant / Funding (institution): Novocure. N. Chaput: Research grant / Funding (institution): Cytune Pharma, GSK, Sanofi; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Speaker Bureau / Expert testimony: Sanofi. B. Besse: Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Biogen; Research grant / Funding (institution): Blueprint Medicines; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Celgene; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): GSK; Research grant / Funding (institution): Ignyta; Research grant / Funding (institution): IPSEN; Research grant / Funding (institution): Merck KGaA; Research grant / Funding (institution): MSD; Research grant / Funding (institution): Nektar; Research grant / Funding (institution): Onxeo; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Pharma Mar; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): Spectrum Pharmaceuticals; Research grant / Funding (institution): Takeda; Research grant / Funding (institution): Tiziana Pharma. All other authors have declared no conflicts of interest.

Collapse
Mini Oral session 1 Mini Oral session

92O - Nivolumab plus low-dose ipilimumab as first-line treatment of advanced NSCLC: Overall survival analysis of checkmate 817

Presentation Number
92O
Lecture Time
11:05 - 11:10
Speakers
  • F. Barlesi (Marseille, CEDEX 20, France)
Session Name
Location
Room C, Geneva Palexpo, Geneva, Switzerland
Date
12.12.2019
Time
10:45 - 11:45
Authors
  • F. Barlesi (Marseille, CEDEX 20, France)
  • C. Audigier-Valette (Toulon, France)
  • E. Felip (Barcelona, Spain)
  • T. Ciuleanu (Cluj-Napoca, Romania)
  • K. Jao (Montreal, QC, Canada)
  • E. Rijavec (Genova, Italy)
  • L. Urban (Matrahaza, Hungary)
  • J. Aucoin (Trois-Rivières, Canada)
  • C. Zannori (Terni, Italy)
  • K. Vermaelen (Ghent, Belgium)
  • O. Arén Frontera (Santiago, Chile)
  • N. Ready (Durham, NC, United States of America)
  • A. Curioni (Zurich, Switzerland)
  • H. Linardou (Athens, Greece)
  • E. Poddubskaya (Moscow, Russian Federation)
  • J. Fischer (Löwenstein, Germany)
  • R. Pillai (Atlanta, GA, United States of America)
  • S. Li (Princeton, NJ, United States of America)
  • A. Acevedo (Princeton, NJ, United States of America)
  • L. Paz-Ares (Madrid, Spain)

Abstract

Background

Nivolumab (NIVO) + ipilimumab (IPI) combination demonstrated improved overall survival (OS) benefits vs chemotherapy as first-line treatment for advanced NSCLC in both tumor programmed death ligand 1 (PD-L1) expression ≥ 1% and < 1% in CheckMate 227. CheckMate 817 is a multi-cohort, single arm, phase IIIb study evaluating the safety of flat-dose NIVO + weight-based low-dose IPI in advanced NSCLC. Preliminary safety and efficacy results were previously reported for cohorts A and A1. Here we present additional safety data and OS in these cohorts.

Methods

Patients with previously untreated stage IV or recurrent NSCLC, and no known sensitizing EGFR or ALK alterations, were eligible regardless of PD-L1 expression. Cohort A (n = 391) had ECOG performance status (PS) 0–1; cohort A1 (special populations; n = 198) had ECOG PS 2 or a specified comorbidity (asymptomatic untreated brain metastases, hepatic or renal impairment, or HIV). Patients were treated with NIVO 240 mg Q2W + low-dose IPI 1 mg/kg Q6W for 2 years or until disease progression/unacceptable toxicity. Safety in cohort A was the primary endpoint; efficacy endpoints were secondary/exploratory; A1 safety and efficacy analyses were exploratory.

Results

Baseline characteristics apart from ECOG PS and comorbidities were similar between cohorts. With minimum follow-up of 21 months (A) and 14 months (A1), median OS was 17.0 months and 9.9 months, respectively. At 1 year, 60% of patients in A and 47% of patients in A1 were alive. OS by PD-L1 expression and tumor mutational burden levels will be presented. The safety profile (type and rate of treatment-related adverse events [TRAEs]) was consistent between the cohorts. The range of median time to onset of select TRAEs was similar between cohorts A (2–26 weeks) and A1 (2–21 weeks). The majority of select TRAEs have resolved (40%–100%).

Conclusion

Select TRAE profile of NIVO + low-dose IPI was similar between cohorts A and A1. Durable OS outcomes were observed with first-line NIVO+IPI in patients with advanced NSCLC (cohort A) and were comparable to CheckMate 227; although as expected, comorbidities and/or poor performance status impacted outcomes in cohort A1.

Clinical trial identification

NCT02869789.

Editorial acknowledgement

Writing and editorial assistance was provided by Mhairi Laird, PhD, of Caudex and funded by Bristol-Myers Squibb.

Legal entity responsible for the study

Bristol-Myers Squibb.

Funding

Bristol-Myers Squibb.

Disclosure

F. Barlesi: Honoraria (self): AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Novartis, Merck, MSD, Pierre Fabre, Pfizer, Takeda; Advisory / Consultancy: AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Novartis, Merck, MSD, Pierre Fabre, Pfizer, Takeda; Research grant / Funding (institution): AbbVie, ACEA, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eisai, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Genentech, Ipsen, Ignyta, Innate Pharma, Loxo, Novartis, Medimmune, Merck, MSD, Pierre Fabre, Pfizer, Sanofi-Aventis,; Non-remunerated activity/ies: Principal Investigator for AstraZeneca, Bristol-Myers Squibb, Merck, Pierre Fabre and Roche sponsored trials (or ISR). C. Audigier-Valette: Honoraria (self): AbbVie, Pfizer; Honoraria (institution): Roche, MSD, Bristol-Myers Squibb, AstraZeneca; Advisory / Consultancy: Roche, MSD, Bristol-Myers Squibb, AstraZeneca, AbbVie, Pfizer. E. Felip: Advisory / Consultancy: AbbVie, AstraZeneca, Blue Print Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Guardant Health, Janssen, Medscape, Merck KGaA, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Takeda, TouchTime; Speaker Bureau / Expert testimony: AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck KGaA, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Takeda. T-E. Ciuleanu: Advisory / Consultancy: Astellas, Janssen, Bristol-Myers Squibb, Merck Serono, Amgen, Roche, Pfizer, Boehringer Ingelheim, Lilly, AstraZeneca, MSD, Sanofi, Novartis, Servier, AD Pharma. K. Jao: Advisory / Consultancy: AbbVie, AstraZeneca, Bayer, Bristol-Myers Squibb, Pfizer, Merck, Takeda, Roche; Speaker Bureau / Expert testimony: AstraZeneca/CIOSK. J-S. Aucoin: Advisory / Consultancy: AstraZeneca, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Roche; Speaker Bureau / Expert testimony: AstraZeneca, Merck, Pfizer, Roche. K. Vermaelen: Honoraria (self): MSD, Roche; Honoraria (institution): Bristol-Myers Squibb; Advisory / Consultancy: MSD, Bristol-Myers Squibb, Roche; Research grant / Funding (institution): Bristol-Myers Squibb. O. Arén Frontera: Full / Part-time employment: Pfizer. N. Ready: Honoraria (self): Bristol-Myers Squibb, AstraZeneca, G1 therapeutics, Merck, Genentech, AbbVie, Bristol-Myers Squibb – unbranded speaker, Celgene – unbranded speaker; Advisory / Consultancy: Bristol-Myers Squibb, AstraZeneca, G1 therapeutics, Merck, Genentech, AbbVie; Speaker Bureau / Expert testimony: Bristol-Myers Squibb – unbranded speaker, Celgene – unbranded speaker; Research grant / Funding (self): Merck investigator-initiated trial. A. Curioni: Advisory / Consultancy: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, MSD, Roche, Pfizer, Takeda. H. Linardou: Advisory / Consultancy: Bristol-Myers Squibb, MSD, AstraZeneca, Roche; Speaker Bureau / Expert testimony: AstraZeneca. R. Pillai: Research grant / Funding (self): Bristol-Myers Squibb. S. Li: Full / Part-time employment: Bristol-Myers Squibb. A. Acevedo: Shareholder / Stockholder / Stock options: Bristol-Myers Squibb; Full / Part-time employment: Bristol-Myers Squibb. L. Paz-Ares: Honoraria (self): Roche, MSD, Lilly, Novartis, Boehringer Ingelheim, AstraZeneca, Amgen, Sanofi, Pharmamar, Pfizer, Bristol-Myers Squibb, Merck, Takeda, Celgene, Servier, Sysmex, Incyte, Ipsen, Adacap, Bayer, Blueprint; Leadership role: Altum Sequencing; Research grant / Funding (institution): MSD, AstraZeneca, Pfizer, Bristol-Myers Squibb. All other authors have declared no conflicts of interest.

Collapse
Mini Oral session 1 Mini Oral session

47O - Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, non-small cell lung cancer or urothelial cancer in routine clinical practice

Presentation Number
47O
Lecture Time
11:10 - 11:15
Speakers
  • P. Luhn (South San Francisco, United States of America)
Session Name
Location
Room C, Geneva Palexpo, Geneva, Switzerland
Date
12.12.2019
Time
10:45 - 11:45
Authors
  • A. Drakaki (Los Angeles, United States of America)
  • P. Luhn (South San Francisco, United States of America)
  • H. Wakelee (Stanford, CA, United States of America)
  • P. Dhillon (South San Francisco, CA, United States of America)
  • M. Kent (Hoboken, NJ, United States of America)
  • J. Shim (Basel, Switzerland)
  • V. Degaonkar (South San Francisco, CA, United States of America)
  • T. Hoang (South San Francisco, CA, United States of America)
  • V. McNally (Welwyn Garden City, United Kingdom)
  • S. Chui (South San Francisco, United States of America)
  • R. Gutzmer (Hanover, Germany)

Abstract

Background

Corticosteroids (CS) are often prescribed for patients (pts) with cancer to alleviate disease symptoms, manage treatment-related adverse events, or treat underlying comorbidities. Immunosuppressive properties of CS may impact the effectiveness of cancer immunotherapy (CIT) if given concomitantly. This study explored the association of baseline CS use with outcomes in CIT-treated pts with advanced melanoma (aMel), advanced non-small cell lung cancer (aNSCLC) or advanced urothelial cancer (aUC).

Methods

Retrospective observational study of pts in the Flatiron Health de-identified electronic health record–derived database diagnosed Jan 2011-Jun 2017 with aMel, aNSCLC or aUC and treated with CIT only in any line. Baseline CS use was defined as intravenous or intramuscular administration or oral orders ≤14 days prior and up to 30 days after start of CIT. Association of baseline CS use with overall survival (OS) was estimated using multivariable Cox proportional hazards models adjusted for key baseline characteristics.

Results

Most pts were white males aged 66-72 years at first CIT treatment. Most pts with aNSCLC (56%) or aUC (59%) received 2L CIT; patients with aMel (89%) used CIT in 1L. Pts taking baseline CS (19%-30%) were more likely to have stage IV disease at diagnosis, brain metastases, liver metastases (aNSCLC, aUC) and poorer ECOG PS scores (aUC) at baseline. The use of baseline CS was associated with a 23%-47% higher risk of death compared with no use in multivariable models.

Conclusion

Baseline CS was associated with shorter survival for pts treated with CIT and not explained by measured confounders. These results suggest that avoidance of CS should be considered at the initiation of treatment, when possible and appropriate, to maximize the potential benefits of CIT. Further studies are needed to confirm these observations.

Patient characteristics by BL CS use, OS by CS use

aNSCLC (n = 862)
aMel (n = 742)
aUC (n = 609)
CS (n = 258)No CS (n = 604)CS (n = 182)No CS (n = 560)CS (n = 116)No CS (n = 493)
Age at CIT start, mean (SD), years68.2 (9.6)68.5 (9.8)66.1 (13.0)66.9 (13.0)73.0 (8.9)72.6 (8.9)
Female484528312726
Non-Hispanic white717085856875
CCI <2858793868183
Treatment sequence
1L191990882630
2L55568105955
Stage IV at diagnosis716134a29a42a35a
ECOG PS ≥ 2 at CIT start17159113421
BL metastases
Liver271724273424
Lung0061562736
Bone454028263431
Brain2619312152
Multivariableb OS, HR (95% CI), CS use vs. no CS use (reference)
Model 11.35 (1.12, 1.62)1.23 (0.97, 1.57)1.47 (1.14, 1.90)
Model 21.34 (1.12, 1.61)1.24 (0.97, 1.57)1.44 (1.12, 1.87)

BL, baseline; CCI, Charlson Comorbidity Index; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio.

Values are % unless noted.

Significant missing stage information (22% for aMel, 49% aUC vs. 2% aNSCLC).

Multivariable models adjusted for age at CIT start, stage at diagnosis, race/ethnicity, sex, ECOG PS and CCI at CIT start, treatment sequence, brain metastases at CIT start, smoking status (aNSCLC, aUC), histology (aNSCLC), grade (aUC) in model 1 and prior steroid use in model 2.

Editorial acknowledgement

Medical writing assistance for this abstract was provided by Jeff Frimpter, PhD, of Health Interactions, Inc., and funded by F. Hoffmann-La Roche, Ltd.

Legal entity responsible for the study

F. Hoffmann-La Roche, Ltd.

Funding

F. Hoffmann-La Roche, Ltd.

Disclosure

A. Drakaki: Advisory / Consultancy, Travel / Accommodation / Expenses: AZ; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Radmetrix; Research grant / Funding (institution): Kite Pharma; Travel / Accommodation / Expenses: ElI Lilly; Shareholder / Stockholder / Stock options: Urogen; Shareholder / Stockholder / Stock options: Allogene; Shareholder / Stockholder / Stock options: Kynan Pharma; Full / Part-time employment: Ucla. P. Luhn: Shareholder / Stockholder / Stock options, Full / Part-time employment: Genentech. H. Wakelee: Honoraria (self), Research grant / Funding (institution): Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses, ad board participation (compensated): AZ; Advisory / Consultancy, Research grant / Funding (institution), ad board participation (compensated): Xcovery; Advisory / Consultancy, ad board participation (compensated): Janssen; Advisory / Consultancy, ad board participation (compensated): Mirati; Advisory / Consultancy, ad board participation (compensated): Daiichi Sankyo; Advisory / Consultancy, Research grant / Funding (institution), Advisory board (not compensated): Merck; Advisory / Consultancy, Advisory board (not compensated): Takeda; Advisory / Consultancy, Research grant / Funding (institution), Advisory board (not compensated): Genentech/Roche; Advisory / Consultancy, Advisory board (not compensated): Cellworks; Research grant / Funding (institution): ACEA Biosciences; Research grant / Funding (institution): Arrys Therapeutics; Research grant / Funding (institution): Pharmacyclics; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Cellgene; Research grant / Funding (institution): Clovis Oncology; Research grant / Funding (institution): Exelixis; Research grant / Funding (institution): Gilead; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Pfizer. P.K. Dhillon: Full / Part-time employment: Genentech. J. Shim: Full / Part-time employment: Roche. V. Degaonkar: Shareholder / Stockholder / Stock options, Full / Part-time employment: Genentech/Roche. T. Hoang: Full / Part-time employment: Genentech. V. McNally: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche. S.Y. Chui: Shareholder / Stockholder / Stock options, Full / Part-time employment: Genentech/Roche. R. Gutzmer: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Novartis; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy: Almirall-Hermal; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Amgen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck-Serono; Honoraria (self): AZ; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: SUN; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pierre-Fabre; Advisory / Consultancy: 4SC; Advisory / Consultancy: Incyte; Advisory / Consultancy: Takeda; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Johnson & Johnson. All other authors have declared no conflicts of interest.

Collapse
Mini Oral session 1 Mini Oral session

93O - First results of phase I/II studies evaluating viral vector-based heterologous prime/boost immunotherapy against predicted HLA class I neoantigens demonstrate CD8 T cell responses in patients with advanced cancers

Presentation Number
93O
Lecture Time
11:15 - 11:20
Speakers
  • M. Johnson (Nashville, TN, United States of America)
Session Name
Location
Room C, Geneva Palexpo, Geneva, Switzerland
Date
12.12.2019
Time
10:45 - 11:45
Authors
  • M. Johnson (Nashville, TN, United States of America)
  • A. Spira (Fairfax, United States of America)
  • D. Carbone (Columbus, OH, United States of America)
  • C. Drake (New York, United States of America)
  • B. Henick (New York, United States of America)
  • M. Ingham (New York, United States of America)
  • K. Caldwell (Emeryville, CA, United States of America)
  • S. Chan (Emeryville, NY, United States of America)
  • M. Hart (Emeryville, United States of America)
  • A. Malloy (Emeryville, NY, United States of America)
  • E. Maloney (Emeryville, NY, United States of America)
  • C. Palmer (Emeryville, NY, United States of America)
  • A. Yang (Emeryville, CA, United States of America)
  • M. Zhong (Emeryville, CA, United States of America)
  • P. Basciano (Lawrenceville, NJ, United States of America)
  • E. Bournazou (Lawrenceville, NJ, United States of America)
  • A. Ferguson (Emeryville, United States of America)
  • D. Catenacci (Chicago, United States of America)

Abstract

Background

Genetically engineered viruses induce strong T-cell responses against infectious pathogens in humans. Virus-based vectors expressing non-self tumor antigens are an attractive option to induce strong tumor-specific T cells.

Methods

Two ongoing phase I/II trials, GO-004 and GO-005, deploy an heterologous prime/boost immunotherapy to target neoantigens in combination with immune checkpoint blockade. The prime is a modified chimpanzee adenovirus. Boosts use a self-amplifying mRNA formulated in lipid nanoparticles. Both prime and boosts express the same 20 neoantigens. In GO-004, patient-specific neoantigens are predicted using a proprietary machine learning-based HLA Class I prediction model (EDGE) and incorporated into a patient-specific immunotherapy. GO-005 uses an off-the-shelf immunotherapy expressing shared neoantigens administered to patients with a matching tumor mutation and HLA Class I allele for antigen presentation.

Results

To date, 5 patients with advanced gastroesophageal adenocarcinoma, lung and colorectal (MSS) cancers have been treated in combination with nivolumab in both studies. No DLTs have been observed and treatment-related adverse events include reversible Grade 1/2 injection site reactions (3/5), fever (3/5, including 1 patient with 2 transient Grade 2 SAEs), skin rash (1/5), dermatitis (1/5), and asymptomatic Grade 3 CK elevation (1/5). In the first 3 patients analyzed to date in GO-004, overnight IFNg ELISpot assays revealed neoantigen-specific CD8 T-cell responses 2-4 weeks after priming that were further enhanced with subsequent boosts to levels >500 spots/106 PBMCs. Broad polyfunctional CD8 T-cell responses to multiple neoantigens were observed including de novo priming of T cells.

Conclusion

Patients treated with a heterologous viral vector-based immunotherapy produce remarkable CD8 T-cell responses specific for predicted HLA Class I neoantigens. These results demonstrate proof-of-concept for the immunogenicity of our novel prime/boost approach. Treatment was well tolerated without DLTs. Additional patients and data will be presented.

Clinical trial identification

NCT03639714; NCT03953235.

Legal entity responsible for the study

Gritstone Oncology.

Funding

Gritstone Oncology.

Disclosure

M.L. Johnson: Research grant / Funding (institution), Travel / Accommodation / Expenses: Genentech/Roche; Research grant / Funding (institution), Travel / Accommodation / Expenses: Boehringer Ingelheim; Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck; Research grant / Funding (institution), Travel / Accommodation / Expenses: Incyte; Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Research grant / Funding (institution): Guardant Health; Research grant / Funding (institution), Travel / Accommodation / Expenses: Bristol-Myers Squibb; Research grant / Funding (institution): Oncomed; Research grant / Funding (institution): BerGenBio; Research grant / Funding (institution): Lilly; Travel / Accommodation / Expenses: Sysmex; Travel / Accommodation / Expenses: Vapotherm; Research grant / Funding (institution), Travel / Accommodation / Expenses: EMD Serono; Research grant / Funding (institution), Travel / Accommodation / Expenses: Daiichi Sankyo; Travel / Accommodation / Expenses: Exelixis; Research grant / Funding (institution), Travel / Accommodation / Expenses: AbbVie; Research grant / Funding (institution), Travel / Accommodation / Expenses: Gritstone Oncology; Research grant / Funding (institution): Genocea; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): Kadmon; Research grant / Funding (institution): Janssen; Research grant / Funding (institution): Mirati; Research grant / Funding (institution): Genmab; Research grant / Funding (institution): StemCentRx; Research grant / Funding (institution): Novarits; Research grant / Funding (institution): Checkpoint Therapeutics; Research grant / Funding (institution): Array BioPharma; Research grant / Funding (institution): Regeneron; Research grant / Funding (institution): Hengrui Pharmaceutical; Research grant / Funding (institution): Lycera; Research grant / Funding (institution): BeiGene; Research grant / Funding (institution): Tarveda Therapeutics; Research grant / Funding (institution): Loxo; Research grant / Funding (institution): Foundation Medicine; Research grant / Funding (institution): Mersana; Research grant / Funding (institution): CytomX Therapeutics; Research grant / Funding (institution): Dynavax; Research grant / Funding (institution): Bridie; Research grant / Funding (institution): Corvus; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Adaptimmune; Research grant / Funding (institution): Syndax; Research grant / Funding (institution): G1 Therapeutics; Research grant / Funding (institution): Clovis; Research grant / Funding (institution): Acerta Pharma. A. Spira: Research grant / Funding (self), Research grant / Funding (institution): Gritstone Oncology. D.P. Carbone: Research grant / Funding (institution): Gritstone Oncology; Research grant / Funding (self), Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy: Abbvie; Advisory / Consultancy: Agenus; Advisory / Consultancy: Amgen; Advisory / Consultancy: Ariad; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Biocept; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Celgene; Advisory / Consultancy: Clovis; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Foundation Medicine; Advisory / Consultancy: Genentech/Roche; Advisory / Consultancy: Glaxo-Smith-Kline; Advisory / Consultancy: Guardant Health; Advisory / Consultancy: Helsinn; Advisory / Consultancy: Humana; Advisory / Consultancy: Incyte; Advisory / Consultancy: Inivata; Advisory / Consultancy: Inovio; Advisory / Consultancy: Janssen; Advisory / Consultancy: Kyowa Kirin; Advisory / Consultancy: Loxo Oncology; Advisory / Consultancy: Merck; Advisory / Consultancy: MSD; Advisory / Consultancy: Nexus Oncology; Advisory / Consultancy: Novartis Oncology; Advisory / Consultancy: Palobiofarma; Advisory / Consultancy: Pfizer; Advisory / Consultancy: prIME Oncology; Advisory / Consultancy: Stemcentrx; Advisory / Consultancy: Takeda Oncology; Advisory / Consultancy: Teva. C. Drake: Research grant / Funding (institution): Gritstone Oncology; Advisory / Consultancy, Research grant / Funding (self), Licensing / Royalties: Bristol-Myers Squibb; Advisory / Consultancy, Shareholder / Stockholder / Stock options: Compugen; Advisory / Consultancy, Shareholder / Stockholder / Stock options: Potenza; Advisory / Consultancy, Research grant / Funding (self), Licensing / Royalties: Janssen; Advisory / Consultancy: Merck; Advisory / Consultancy: Agenus; Advisory / Consultancy: Roche/Genentech; Advisory / Consultancy: Tizona Therapeutics; Shareholder / Stockholder / Stock options: Harpoon; Advisory / Consultancy, Shareholder / Stockholder / Stock options: Kleo; Advisory / Consultancy, Shareholder / Stockholder / Stock options: Werewolf; Advisory / Consultancy: Bayer; Advisory / Consultancy: Merck-Serono; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: Shattuck Labs. B. Henick: Advisory / Consultancy: Boehringer Ingelheim; Research grant / Funding (institution): Gritstone Oncology. M. Ingham: Research grant / Funding (institution): Gritstone Oncology. K. Caldwell: Shareholder / Stockholder / Stock options, Full / Part-time employment: Gritstone Oncology. S. Chan: Shareholder / Stockholder / Stock options, Full / Part-time employment: Gritstone Oncology. M. Hart: Shareholder / Stockholder / Stock options, Full / Part-time employment: Gritstone Oncology. A. Malloy: Shareholder / Stockholder / Stock options, Full / Part-time employment: Gritstone Oncology. E. Maloney: Shareholder / Stockholder / Stock options, Full / Part-time employment: Gritstone Oncology. C. Palmer: Shareholder / Stockholder / Stock options, Full / Part-time employment: Gritstone Oncology. A. Yang: Shareholder / Stockholder / Stock options, Full / Part-time employment: Gritstone Oncology. M. Zhong: Shareholder / Stockholder / Stock options, Full / Part-time employment: Gritstone Oncology. P. Basciano: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb. E. Bournazou: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb. A.R. Ferguson: Shareholder / Stockholder / Stock options, Full / Part-time employment: Gritstone Oncology. D. Catenacci: Honoraria (self), Research grant / Funding (institution): Gritstone Oncology; Honoraria (self): Merck; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Astellas; Honoraria (self): Lilly; Honoraria (self): Taiho; Honoraria (self): Five Prime; Speaker Bureau / Expert testimony: Guardant Health, Inc.; Speaker Bureau / Expert testimony: Foundation Medicine; Speaker Bureau / Expert testimony: Tempus; Honoraria (self): Roche/Genentech; Honoraria (self): Amgen.

Collapse
Mini Oral session 1 Mini Oral session

Discussion led by Moderators

Lecture Time
11:20 - 11:45
Speakers
  • I. Melero (Pamplona, Spain)
  • J. Haanen (Amsterdam, Netherlands)
Session Name
Location
Room C, Geneva Palexpo, Geneva, Switzerland
Date
12.12.2019
Time
10:45 - 11:45
Authors
  • I. Melero (Pamplona, Spain)
  • J. Haanen (Amsterdam, Netherlands)